Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

triplemintcookie Dec. 13 at 6:01 PM

$BTAI opinion is going to run up to FDA decision in the spring. Then the share offering, but with approval then the share offering is purchased higher than today’s price. Hang in there if your cost average is below $2.50.

1 · Reply

kingoftrade2000 Dec. 13 at 1:37 PM

$BTAI - everybody seems to be analyst here on BTAI, but the fact is, you don't know shit and I don't know shit too. We all jump in when its up $0.15 and when it gets down $0.15 we start dumping it out of fear. It's because the managements are piece of shit.

0 · Reply

Mg_1970 Dec. 13 at 8:37 AM

$BTAI probably I'll take the loss and I'll sell it, I'm tired, probably company will pump it for a potential dilution, they have no money. Cash Position (Millions) The company has 5.3 months of cash left based on quarterly cash burn of -$14.47M and estimated current cash of $25.4M.

0 · Reply

FoobarSwopey Dec. 12 at 5:37 PM

$BTAI folks, I'd hate to say it, short or long term, this company's stock is going no where. Again, don't ask me for specific sources, but I think the Minnesota fraud thing will eventually be revealed with possible tie-ins or connections to this company. It's only a matter of time for DOJ to dig deeper and reveal this. Dig deep into research and such with Somalia and the leadership and research team of btai. Just a guess or inkling on my part.

2 · Reply

SrTxan Dec. 12 at 2:45 PM

$BTAI As can be seen in the public reports, short positions have decreased by approximately 43%, from 1,580,000 shares to 909,000.

1 · Reply

stock_runner1 Dec. 12 at 1:59 PM

$BTAI every now and then I come back to this stock and remind my self not to buy the hype . Classic pump n dump and it's the same bag holders in here from 6 months ago praying this shit will turn around

1 · Reply

MarkTheGenius Dec. 12 at 12:29 AM

$BTAI I think your explanation of this entire situation is intelligent and accurate. It explains why the stock has not gotten to $10+. Good job. With that in mind, we'll make some money off the stock in the short term. We're used to Pump and Dump here. I'm still Bullish

0 · Reply

BurntReynolds Dec. 11 at 5:55 PM

$BTAI Anyone vote yet? What's your take on it?

1 · Reply

Bob584 Dec. 11 at 5:29 PM

$BTAI There are a lot of institutions that were into this stock before, and they're starting to trickle back.

0 · Reply

FoobarSwopey Dec. 11 at 2:29 PM

$BTAI Regarding the last poster... I hear you and I want to believe you. However, they are in massive debt. They also know that many of us are just sitting back and waiting to bank in on this stock once it hits above the 3 dollar mark or higher which will result in a massive, massive selloff, leaving them scrambling to pay their bills and nice cushy salaries. Most importantly, the percentage of fraud cases in the Somali population in Minnesota that make up the forecast for btai and their breakthrough drug has greatly alarmed their management and has them scrambling to recalculate their future earnings forecast. Regardless of the approval of phase 3 from the FDA, this stock price will remain low. Heck, I wouldn't even doubt that they have ties to what is going on in Minnesota. If that's the case, this company is history.

2 · Reply

BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript

Dec 3, 2025, 7:00 AM EST - 10 days ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Nov 12, 2025, 7:00 AM EST - 4 weeks ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Oct 24, 2025, 11:38 AM EDT - 7 weeks ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 14, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Sep 18, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 6:41 PM EDT - 3 months ago

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 3 months ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 3 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 3 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 3 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 3 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 3 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 13, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 7:55 AM EDT - 4 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 7 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 10 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 10 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 11 months ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

triplemintcookie Dec. 13 at 6:01 PM

1 · Reply

kingoftrade2000 Dec. 13 at 1:37 PM

0 · Reply

Mg_1970 Dec. 13 at 8:37 AM

0 · Reply

FoobarSwopey Dec. 12 at 5:37 PM

2 · Reply

SrTxan Dec. 12 at 2:45 PM

$BTAI As can be seen in the public reports, short positions have decreased by approximately 43%, from 1,580,000 shares to 909,000.

1 · Reply

stock_runner1 Dec. 12 at 1:59 PM

1 · Reply

MarkTheGenius Dec. 12 at 12:29 AM

0 · Reply

BurntReynolds Dec. 11 at 5:55 PM

$BTAI Anyone vote yet? What's your take on it?

1 · Reply

Bob584 Dec. 11 at 5:29 PM

$BTAI There are a lot of institutions that were into this stock before, and they're starting to trickle back.

0 · Reply

FoobarSwopey Dec. 11 at 2:29 PM

2 · Reply

Thekiss320 Dec. 11 at 1:52 PM

$BTAI Everyone freaking out at these levels is ignoring the math. You’ve got a beaten-down biotech trading like it’s already dead, but the optionality is massive from here. Risk is literally the last couple of bucks… upside is a full re-rating if ANY real progress or partnership drops. This is where big money quietly accumulates while retail cries in the comments. I’m holding my shares and treating this as a lottery ticket with real science behind it – if it wakes up, it won’t be a 10–15% move, it will be a multi-bag gap that leaves everyone who sold down here chasing. I’m staying strapped in.

1 · Reply

DariHendrix Dec. 11 at 12:29 PM

$BTAI

0 · Reply

SimpleWinningSetups Dec. 11 at 4:20 AM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $AIRE | Timeframe: 6M / 1D Market Cap: $68.12M • Pattern score: 0.68 • Current price: $0.521 • Peak (window): $1.450 • Trough (post-spike): $0.415 • Pullback: ~71.4% from peak • Move off lows: ~35.9% of peak Stock Plan (educational only) • Entry zone: $0.505 – $0.531 • Scalp target: $0.563 → Est. ROI: ~8.0% • Swing target: $0.834 → Est. ROI: ~60.0% • Protective stop: $0.443 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $BTAI

0 · Reply

Bilipli Dec. 10 at 7:19 PM

$BTAI they still need to hand in phase 3 data to fda and then need months for results from fda, and they don't have enough money... dilute will come again... why buy now...

0 · Reply

Mg_1970 Dec. 10 at 6:39 PM

$BTAI Fucking stock...rejected..rejected 🙄🙄

0 · Reply

MarkTheGenius Dec. 10 at 5:11 PM

$BTAI She's looking much better. Broke resistance.

0 · Reply